AgomAb Therapeutics NV

The latest third quarter data from the National Venture Capital Association (NVCA) and Pitchbook’s Venture Monitor report confirm recent data compiled by Evaluate Pharma, which showed that VC investme

The partners at Andera Life Sciences have been reflecting on a busy week which saw the France-headquartered private equity firm wave goodbye to portfolio company Amolyt Pharma , sold to AstraZeneca

AgomAb Therapeutics NV ’s first nine-figure venture round is the fifth largest this year for a Europe-based company, and ought to see the company through Phase II development of its lead compound, a t

Rising Leaders Home Fibrotic processes are the root cause behind a variety of hard-to-treat diseases, and are key to the scientific approach used by Agomab Therapeutics NV , a Belgian biotech which